Kezar Life Sciences, Inc. (KZR) Receivables - Accured (2022 - 2024)

Kezar Life Sciences (KZR) posted Receivables - Accured of $589000.0 for Q3 2024, up 57.49% sequentially from $374000.0 in Q2 2024.

Kezar Life Sciences, Inc. (KZR) Receivables - Accured (2022 - 2024) Analysis & Trends

Kezar Life Sciences has reported Receivables - Accured for 3 years, with the latest figure at $589000.0 in Q3 2024.

Quarterly Receivables - Accured changed N/A year-over-year to $589000.0 in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $589000.0 (changed N/A YoY) and the FY2023 annual result came in at $695000.0, down 10.21% from the prior year.
Receivables - Accured climbed to $589000.0 in Q3 2024 per KZR's latest filing, from $374000.0 in the prior quarter.
Over five years, Receivables - Accured peaked at $774000.0 in Q4 2022 and troughed at $374000.0 in Q2 2024.
A 3-year average of $616000.0 and a median of $648000.0 in 2024 frame the typical range for Receivables - Accured.
The widest YoY moves for Receivables - Accured: up 10.21% in 2023, down 10.21% in 2023.
Over 3 years, Receivables - Accured stood at $774000.0 in 2022, then slipped by 10.21% to $695000.0 in 2023, then retreated by 15.25% to $589000.0 in 2024.
According to Business Quant data, Receivables - Accured over the past three periods registered $589000.0, $374000.0, and $648000.0 for Q3 2024, Q2 2024, and Q1 2024 respectively.

Download Data